The company reports the drug showed “clinically meaningful improvements” in overall survival.

An investigational drug for glioblastoma more than doubled survival and progression-free time compared to standard rates, reported a new study published in Nature Communications. Glioblastoma is the ...

Welireg significantly improved quality-adjusted survival time over Afinitor in advanced renal cell carcinoma, with a mean Q-TWiST of 17.47 months versus 14.81 months. The relative gain in Q-TWiST with ...

COVID-19 mRNA vaccines significantly increased survival times in patients with advanced lung and skin cancer undergoing immunotherapy. The corresponding study was published in Nature. "The ...

Rybrevant and Lazcluze combination therapy significantly improves overall survival in EGFR-mutated NSCLC compared to Tagrisso monotherapy. The MARIPOSA study showed a 25% reduction in mortality risk ...